Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.56 |
| ▸ | HTR6 | P50406 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12420566 | 0.88 | MAOB (0.58) | MAOBHTR6KCNH2NR4A2PARP10 | |
| Hydrochloric Acid SCHEMBL2194424 | 0.87 | MAOB (0.59) | MAOBHTR6KCNH2NR4A2PARP10 | |
| SCHEMBL12420653 | 0.85 | MAOB (0.51) | MAOBHTR6KCNH2SLC6A2SLC6A4 | |
| SCHEMBL1532769 | 0.84 | MAOB (0.59) | MAOBHTR6KCNH2NR4A2PARP10 | |
| SCHEMBL1476345 | 0.83 | SLC6A2 (0.61) | HTR6KCNH2SLC6A2SLC6A4HTR3A | |
| Hydrochloric Acid SCHEMBL2192010 | 0.83 | MAOB (0.60) | MAOBHTR6KCNH2NR4A2PARP10 | |
| Hydrochloric Acid SCHEMBL1474997 | 0.82 | SLC6A2 (0.60) | HTR6KCNH2SLC6A2SLC6A4HTR3A | |
| SCHEMBL12735859 | 0.82 | MAOB (0.50) | MAOBHTR6KCNH2NR4A2PARP10 | |
| SCHEMBL1532864 | 0.81 | MAOB (0.52) | MAOBHTR6KCNH2SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL1532794 | 0.81 | MAOB (0.51) | MAOBHTR6KCNH2NR4A2PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | MAOB 222/4885HTR6 3435/4885KCNH2 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.